focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,186.00
Bid: 12,184.00
Ask: 12,186.00
Change: 14.00 (0.12%)
Spread: 2.00 (0.016%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AstraZeneca finally reaches vaccine shipping milestone to EU that was due in January

Mon, 10th May 2021 16:37

By Francesco Guarascio

BRUSSELS, May 10 (Reuters) - AstraZeneca Plc has
delivered 50 million doses of its COVID-19 vaccine to European
Union countries, according to EU's latest supply data, a
milestone it was originally due to hit in January.

Repeated cuts to supplies, which contributed to delays in
the EU's vaccination drive, pushed the European executive
commission to sue the Anglo-Swedish drugmaker in late April in a
bid to get more doses by mid-year.

AstraZeneca had shipped nearly 50 million doses as of May 7,
an EU official told Reuters on Monday, citing the latest EU
internal figures on vaccine supplies.

In mid-March, the company had pledged to deliver 50.2
million doses to the EU by the end of April, an AstraZeneca
document seen by Reuters shows.

But AstraZeneca had shipped only 47.6 million doses by the
evening of April 30, a spokesman for the company said, adding
that other doses were sent over the first weekend of May and in
the following days "following requests to not ship to a few
countries that had public holidays during this period".

Immediately after the EU sued the company, AstraZeneca
issued a statement on April 26 saying it would deliver "almost
50 million doses to European countries by the end of April".

Under its contract with the EU, the company had committed to
its "best reasonable efforts" to deliver 300 million doses by
the end of June, of which 70 million were supposed to be
delivered by the end of January.

Citing production problems and export restrictions,
AstraZeneca in March said it would deliver to the EU only 100
million doses by the end of June. It delivered 30 million in
total by the end of March.

The vaccine was approved for use in the EU in late January,
but the EU Commission has said AstraZeneca should have applied
earlier.
(Reporting by Francesco Guarascio; Editing by Bill Berkrot)

More News
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.